Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis

Официальное название

Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)

Обзор

A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

Подробное описание

Acute deep venous thrombosis (DVT) is associated with development of post-thrombotic syndrome (PTS). Early removal of iliofemoral thrombosis by percutaneous mechanical thrombectomy (PMT) may reduce the incidence of PTS. There is currently a lack of research on which device is optimal for thrombus removal. The aim of this study is to conduct a multicenter, observational, prospective cohort study in patients with acute iliofemoral deep vein thrombosis (DVT), performing a head-to-head comparison of two different types of mechanical thrombectomy devices - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

Вмешательства

• Процедура Percutaneous mechanical thrombectomy by ClotTriever System
  The procedure is performed via the ipsilateral popliteal vein access or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using stent retriever devices. Available stent retriever devices include curr
• Процедура Percutaneous mechanical thrombectomy by aspiration or rheolytic thrombectomy
  The procedure is performed via the ipsilateral calf deep vein access, the ipsilateral popliteal vein access, or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using mechanical aspiration thrombect

Первичные конечные точки

• Incidence of PTS [Срок оценки: At 24 months]

Вторичные конечные точки (7)

• Incidence of moderate-to-severe PTS [Срок оценки: at 6, 12, and 24 months]
• Clinical classification of Clinical-Etiology-Anatomy-Pathophysiology (CEAP) [Срок оценки: at 6, 12, and 24 months]
• Patency rate of the ipsilateral iliofemoral vein [Срок оценки: at 12 months and 24 months]
• Incidence of PTS [Срок оценки: Assessed by the Villalta score]
• Recurrence rate of symptomatic Deep Vein Thrombosis (DVT) [Срок оценки: at 24 months]
• Rate of re-intervention [Срок оценки: at 24 months]
• Quality of life score [Срок оценки: at 6, 12, and 24 months]

Критерии участия

Критерии включения

• Aged between 18 and 85 years;
• Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;
• Time from symptom onset to endovascular treatment ≤ 14 days;
• Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;
• Patients sign the informed consent form.

Критерии исключения

• Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;
• Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb;
• Known allergy to heparin, low molecular weight heparin, contrast agents, etc.
• Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.
• Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.
• Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min;
• Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.
• Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or platelet count < 80,000/mL;
• History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;
• Pregnant women;
• Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy < 24 months
• Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;
• Patients unwilling to participate in this trial.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Китай · 1 центр

• Renji hospital — Шанхай

Идентификаторы

NCT: NCT07622212 · The COMET Study

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗